SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?


To: IRWIN JAMES FRANKEL who wrote (45)12/1/2001 12:40:18 AM
From: Vector1  Read Replies (1) | Respond to of 118
 
Irwin,
Why do you think the ramp has been modest. The rund rate is approaching $140m The following are the latest numbers I have seen on scripts from Warburg.

Cholesterol Reducers 5% 32%
Niaspan (KOSP) NRX-18,844
nrx market share-15.9%
one week change-0.8%
4 week change -1.1%
4 week ave growth 2.6%
year over year growth 45%
latest forcast $84
annualized run rate $142